Tibolone and sinomenine were reported to alleviate astrocytic and microglial reactions and mobilization, respectively, decreasing NLRP3 inflammasome activation and EAE severity, which further supports the pathogenic role of the NLRP3 inflammasome in MS (Kiasalari et al., 2021; Mancino et al., 2022). Here, NLRP3 is linked to myeloid sarcoma.